Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multiple-dose study of ACP-001 in adult growth hormone deficiency
2010-021523-28Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ACP-001 in growth hormone deficiency (GHD) (4 arms), sponsored by Ascendis Pharma. Primary endpoints: Pharmacokinetics of ACP-001, Safety and tolerability of ACP-001 and 1 more. Started Jul 2010; status: completed.
02
Drugs
ACP-001
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2010-021523-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021523-28.